US › Healthcare

Fulcrum Therapeutics Inc (FULC)

US · Healthcare · Biotechnology

$3.77-0.53%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-26.2M

EPS

$-0.29

EPS estimate

$-0.21

EPS came in at -0.29 against a street estimate of -0.21 — a miss of 36.5%.

Key statistics

Market cap

$288.4M

Forward P/E

0.0

P/B

0.93

Book value

$4.07

EPS (TTM)

$-1.21

52-week high

$15.74

52-week low

$2.83

50-day MA

$3.75

200-day MA

$7.15

Beta

2.58

Analyst view

Analysts rate Fulcrum Therapeutics Inc a buy (3 buy, 3 hold, 1 sell out of 7) with an average price target of $3.50.

Shareholding

Insiders

3.35%

Institutions

103.40%

Largest institutional holders

Fund	Stake
Suvretta Capital Management, LLC	8.60%
EcoR1 Capital, LLC	8.58%
RA Capital Management, LLC	7.93%
BlackRock Inc	7.07%
BRAIDWELL LP	4.11%
Nantahala Capital Management, LLC	4.00%
D. E. Shaw & Co LP	3.99%
Vanguard Capital Management, LLC	3.53%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Fulcrum Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.